Insulet (PODD) Cash from Operations Growth (3y) (2013 - 2026)
Insulet (PODD) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 27.41% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 22.38% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 30.85% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 168.71% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 12.26% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 65.19% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 43.79% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 9.30% |
| 10 | Insulet | 10.18 Bn | 9.64 Bn | 562.60 Mn | 26.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.18% |
| Mar 31, 2026 | 510.55% |
| Dec 31, 2025 | 53.48% |
| Sep 30, 2025 | 30.39% |
| Jun 30, 2025 | 98.04% |
| Mar 31, 2025 | 88.12% |
| Dec 31, 2024 | 98.19% |
| Sep 30, 2024 | 83.69% |
| Jun 30, 2024 | 68.02% |
| Mar 31, 2024 | 65.04% |
| Dec 31, 2023 | 38.54% |
| Sep 30, 2023 | 8.21% |
| Jun 30, 2023 | 18.56% |
| Mar 31, 2023 | 28.84% |
| Dec 31, 2022 | 2.63% |
| Sep 30, 2022 | 22.16% |
| Jun 30, 2022 | 22.10% |
| Mar 31, 2022 | -60.15% |
| Dec 31, 2021 | -41.58% |
| Sep 30, 2021 | -53.65% |